@article{3108098,
    title = "Patients’ preferences for headache acute and preventive treatment",
    author = "Mitsikostas, D.D. and Belesioti, I. and Arvaniti, C. and Mitropoulou, E. and Deligianni, C. and Kasioti, E. and Constantinidis, T. and Dermitzakis, M. and Vikelis, M. and on behalf of the Hellenic Headache Society",
    journal = "The Journal of Headache and Pain",
    year = "2017",
    volume = "18",
    number = "1",
    publisher = "Springer-Verlag Italia s.r.l.",
    issn = "1129-2369, 1129-2377",
    doi = "10.1186/s10194-017-0813-3",
    keywords = "analgesic agent;  monoclonal antibody;  analgesic agent;  monoclonal antibody, adult;  Article;  chronic cluster headache;  chronic tension headache;  clinical article;  clinical effectiveness;  device safety;  drug safety;  episodic cluster headache;  episodic migraine;  episodic tension headache;  female;  human;  male;  nerve stimulation;  nerve stimulator;  nocebo effect;  outpatient;  patient preference;  priority journal;  prophylaxis;  prospective study;  Q No questionnaire;  questionnaire;  scoring system;  transformed migraine;  Greece;  headache;  implantable neurostimulator;  middle aged;  migraine;  patient preference;  preventive medicine;  psychology;  questionnaire;  subcutaneous drug administration;  utilization;  young adult, Adult;  Analgesics;  Antibodies, Monoclonal;  Female;  Greece;  Headache;  Humans;  Implantable Neurostimulators;  Injections, Subcutaneous;  Male;  Middle Aged;  Migraine Disorders;  Patient Preference;  Preventive Medicine;  Surveys and Questionnaires;  Young Adult",
    abstract = "Background: We aimed to explore patients’ preferences for headache treatments with a self-administered questionnaire including the Q-No questionnaire for nocebo. Methods: Questionnaires from 514 outpatients naïve to neurostimulation and monoclonal antibodies were collected. Results: Patients assessed that the efficacy of a treatment is more important than safety or route of administration. They preferred to use an external neurostimulation device for both acute (67.1%) and preventive treatment (62.8%). Most patients preferred to take a pill (86%) than any other drug given parenterally for symptomatic pharmaceutical treatment. For preventive pharmaceutical treatment, most patients preferred to take a pill once per day (52%) compared to an injection either subcutaneously or intravenously each month (9% and 4%), or three months (15% and 11%). 56.6% of all participants scored more than 15 in Q-No questionnaire indicating potential nocebo behaviors that contributed significantly in their choices. Conclusion: These patient preferences along with efficacy and safety data may help physicians better choose the right treatment for the right person. © 2017, The Author(s)."
}